Search

Your search keyword '"Vesole, David H."' showing total 1,125 results

Search Constraints

Start Over You searched for: Author "Vesole, David H." Remove constraint Author: "Vesole, David H."
1,125 results on '"Vesole, David H."'

Search Results

51. Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

53. The Clinical Characteristics and Epidemiology of Extramedullary Multiple Myeloma over the Past Two Decades

55. Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation

59. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

60. Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

61. Restoring sensitivity to daratumumab with all-transretinoic acid in a patient with daratumumab-refractory multiple myeloma: A case report and review of the literature

62. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients

66. Salvage Second Hematopoietic Cell Transplantation in Myeloma

69. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

70. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

72. TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma.

73. Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors

74. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis

75. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

76. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial

80. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice

81. Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study

82. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

85. Monoclonal Gammopathy of Ocular Significance (MGOS) - a Series of Corneal Manifestations and Treatment Outcomes

86. Inferior Outcomes of Patients with Quad and Penta-Refractory Multiple Myeloma (MM) Compared to Those of Patients Who Have Been Quad and Penta Exposed

90. Effect of a 6-Week Cycle of Nordic Walking Training on Vitamin 25(OH)D 3, Calcium-Phosphate Metabolism and Muscle Damage in Multiple Myeloma Patients–Randomized Controlled Trial.

93. Pembrolizumab, Lenalidomide and Dexamethasone Post Autologous Transplant in Patients with High‐Risk Multiple Myeloma

94. A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

95. A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Catalog

Books, media, physical & digital resources